Adaptimmune Therapeutics PLC – (NASDAQ:ADAP)’s share price traded down 3.7% during mid-day trading on Wednesday . The company traded as low as $8.50 and last traded at $8.58, with a volume of 120,588 shares trading hands. The stock had previously closed at $8.91.

Separately, Leerink Swann reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a report on Sunday, April 24th. Six analysts have rated the stock with a buy rating, Adaptimmune Therapeutics PLC – currently has an average rating of “Buy” and an average price target of $15.63.

The firm’s market capitalization is $615.83 million. The stock’s 50-day moving average price is $9.51 and its 200 day moving average price is $8.95.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last issued its earnings results on Thursday, May 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.03. On average, analysts anticipate that Adaptimmune Therapeutics PLC – will post ($1.29) EPS for the current fiscal year.

In related news, Director Orbimed Advisors Llc bought 1,712,400 shares of the firm’s stock in a transaction that occurred on Tuesday, May 24th. The shares were acquired at an average cost of $10.42 per share, for a total transaction of $17,843,208.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Charles Elliott Sigal bought 45,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The stock was bought at an average price of $1.53 per share, for a total transaction of $68,850.00. Following the completion of the acquisition, the director now directly owns 52,938 shares in the company, valued at $80,995.14. The disclosure for this purchase can be found here.

Several institutional investors recently modified their holdings of ADAP. Jennison Associates LLC boosted its position in shares of Adaptimmune Therapeutics PLC – by 0.3% in the fourth quarter. Jennison Associates LLC now owns 486,948 shares of the company’s stock worth $5,873,000 after buying an additional 1,547 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Adaptimmune Therapeutics PLC – during the fourth quarter worth about $1,700,000. Finally, Tekla Capital Management LLC boosted its position in shares of Adaptimmune Therapeutics PLC – by 5.3% in the fourth quarter. Tekla Capital Management LLC now owns 296,934 shares of the company’s stock worth $3,581,000 after buying an additional 15,000 shares during the last quarter.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.